glp-1 news october 21 2025 What's next for GLP-1 innovation: A primer on the race reshaping pharma and chronic disease care GLP-1 makers could be under

A retrospective real-world study with an observation period of 3 months in a Chinese population with T2D shows a mean weight loss of 12.9% in patients treated with both insulin and beinaglutide without a control comparator group ( 3.1.1.2 Utreglutide (GL0034) Utreglutide is a once-weekly GLP-1 RA administered subcutaneously ( 2 at doses of 450 mcg for 4 weeks (cohort 1), 900 mcg for 4 weeks (cohort 2), and an 8-week dose escalation up to 1,520 mcg (cohort 3) ( 2 , but without T2D, a phase 1 single ascending dose (SAD) trial shows that GL0034 at doses of 1,520 mcg, 2,000 mcg, and 2,520 mcg results in mean weight loss of 2.1%, 1.9%, and 2.5%, respectively, versus 0.3% weight gain for the placebo group one week after administration ( 3.1.1.3 MET-097i MET-097i is an ultra-long acting GLP-1 RA with an elimination half-life of 380 hours ( 3.1.2 Oral 3.1.2.1 Orforglipron Orforglipron is a small molecule non-peptide oral GLP-1 RA administered once daily

Do glutathione injections help with skin brightening

Human PCOS microbiome findings are inconsistent, with variable alpha and beta diversity and bacterial taxa, likely due to heterogeneity in phenotypes such as obesity and insulin resistance

ELA with mild heat Recently, mild heat-based hurdles have been applied as novel food decontamination techniques

Dominissini, D., Moshitch-Moshkovitz, S., Salmon-Divon, M., Amariglio, N

When you push your body during a workout, your stored glutamine levels can drop significantly